Guiding care through
clinically actionable results
Providing actionable answers for treatment guidance and hereditary risk assessment
Colorectal cancer (CRC) is the third most common form of cancer in the U.S., with more than 150,000 new cases diagnosed each year. While sporadic colon cancers are more common, hereditary colon cancers are also frequent, and identification of these affects screening recommendations both for the individual and family members.
Fewer than half of the people found to have colorectal cancer are diagnosed at an early stage, when treatment is most effective. New therapies can reduce tumor size and prolong life, but they also can be costly and not work as intended. The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome.
Webinar — Which Molecular Tests to Order for Colorectal Cancer
This “Specialty Testing” webinar describes the utility of microsatellite instability testing in colorectal cancer care and discusses the limitation of various assays used to diagnose microsatellite instability.